Literature DB >> 9284599

Adverse drugs reactions associated with glaucoma medications.

E Reyes1, N J Izquierdo, M Blasini.   

Abstract

We undertook a non-concurrent prospective study of 191 Puerto Rican patients from August 1993 to April 1994. All patients had open angle glaucoma (OAG) (age ranged from 50 to 80 yrs; mean = 65 yrs). Patient's symptomatology associated to side effects of their glaucoma medicadons was reviewed. Incidence percent of ocular and/or systemic side effects per medication were: levobunolol 45.0%; betaxolol 42.0%; timolol 27.3%; pilocarpine 100%; dipivefrin 14.0%; and acetazolamide 250 mg 64.1%. Incidence percent of ocular and/or systemic side effects of topical beta-blockers used with concomittant medications were determined. Ocular side effects were more frequent in patients using levobunolol 44.2% than in those patients using betaxolol 42.0%, 8.5% of patients using levobunolol did report systemic side effects. No systemic side effects were reported by patients using betaxolol. Ocular side effects in patients using pilocarpine were frequent (100%); whereas the frequency of systemic side effects was low (6.1%). Systemic side effects were common in patients using carbonic anhydrase inhibitors. These results suggest that non-selective and cardio-selective topical Beta-blockers, differ in their ocular or systemic side effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9284599

Source DB:  PubMed          Journal:  Bol Asoc Med P R        ISSN: 0004-4849


  3 in total

1.  Cost-minimisation study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma: in four European countries.

Authors:  Jean-Francois Rouland; Claude Le Pen; Carlos Gouveia Pinto; Patrizia Berto; Gilles Berdeaux
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Graft failure: III. Glaucoma escalation after penetrating keratoplasty.

Authors:  Emily C Greenlee; Young H Kwon
Journal:  Int Ophthalmol       Date:  2008-06       Impact factor: 2.031

3.  Vision related quality of life and topical glaucoma treatment side effects.

Authors:  Jean-Philippe Nordmann; Nadia Auzanneau; Séverine Ricard; Gilles Berdeaux
Journal:  Health Qual Life Outcomes       Date:  2003-12-10       Impact factor: 3.186

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.